Navigation Links
Jennerex Reports Positive Mechanistic Proof-of-Concept Clinical Trial Results Using JX-594 to Treat Metastatic Melanoma
Date:8/2/2011

nd currently markets nine products. Lee's Pharma focuses on several different areas such as cardiovascular and infectious diseases, dermatology, oncology, gynecology and others. It has more than 30 products under different development stages stemming from both internal R&D as well as from the recent acquisition of licensing and distribution rights from various U.S. and European companies. The mission of Lee's is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. Additional information about Lee's Pharma is available on the internet at www.leespharm.com.

About Jennerex

Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594 is currently in two Phase 2 clinical trials in patients with primary liver cancer—an international, randomized, Phase 2 clinical trial, and a Phase 2 study of JX-594 in combination with sorafenib. Published studies designed to establish optimal dose levels and the safety profile of JX-594 have shown its ability to selectively target and cause destruction of a variety of common cancer types. JX-594 and other product candidates under development are designed to attack cancer tumors through three diverse mechanisms of action: the lysis of cancer cells through viral replication, the ablation of the blood supply to tumors through vascular targeting and destruction and the stimulation of the body's immune response against the cancer. Jennerex is headquartered in San Francisco and has related research and development operations in Ottawa, Canada and Pusan, South Korea. For more information about Jennerex, please visit www.jennerex.com.


'/>"/>
SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer
2. Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting
3. Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
4. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
5. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
6. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
7. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
8. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
9. Jennerex Closes $5 Million First Tranche of Series C Financing
10. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
11. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 Earlier this year in ... Sherley, director of the Adult Stem Cell Technology Center, ... overlooked and under appreciated unique property of adult tissue ... Stem Cells: Misunderstood in the Past, Important for the ... participants. He gave the address at the 4th ...
(Date:12/24/2014)... Bethesda, MD (PRWEB) December 23, 2014 ... signed into law H.R. 83, the Omnibus and ... the first time, made hydrocephalus a condition eligible ... Research Programs (CDMRP) administered by the Department of ... conjunction with its allies on Capitol Hill, is ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 ... mercaptan such as its definition, classification, application ... product specification, manufacturing process, and product cost ... and applications. The analysis also covers upstream ... channels, industry development trend and proposals. In ...
(Date:12/24/2014)... 2014 The report expects global cell ... 2019. It also provides a carefully analyzed data about ... for the market. , Full Copy of Report @ ... global market for cell expansion will keep witnessing growth ... this growth to be driven by rapid technological advancements, ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3
... May 5 PLC Systems Inc.,(Amex: PLC ) announced ... its,financial results for the first quarter ended March 31, 2008 ... plans to host a,conference call to discuss those results at ... may be joined via telephone by dialing (800) 638-4930 or ...
... N.J., May 5 Eisai Corporation of North,America ... as,President of Eisai Inc. In her new role, ... Eisai Inc., the U.S. commercial,operation of Eisai Co., ... a strong track record of building,high-performing organizations that ...
... May 5 /PRNewswire-FirstCall/ - Lorus Therapeutics Inc.,("Lorus") ... dedicated in,the research, development and commercialization of ... cancer, announced today that it has,strengthened its ... Dr. Saeid,Babaei to Vice-President of Business Development ...
Cached Biology Technology:PLC Systems to Host First Quarter Conference Call on May 15, 2008 2Eisai Corporation of North America Announces Appointment of Cynthia Schwalm as President, Eisai Inc. 2Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions 2Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions 3Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions 4
(Date:12/10/2014)... SUNNYVALE, California , December 9, 2014 /PRNewswire/ ... Integrate with ITN,s BCARD Platform ... secure, cloud-based enterprise meeting scheduling solutions for business-to-business ... International, the world leader in mobile near-field communication ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , ...
(Date:12/3/2014)... GLENDALE, Ariz. , Dec. 2, 2014 ... biometric hand readers, Inception Technologies is pleased to announce ... it easier for customers to collect the workforce data ... the problems that have been left by existing readers. ... to user interface, connectivity and modern technology. Older models ...
(Date:11/21/2014)...   Atmel® Corporation (NASDAQ: ATML ... technology solutions, today launched the industry,s first family of ... V cc range from 1.7V to 5.5V. The ... 2 C bus communication speeds, and are available with ... ideal for consumer, industrial, computer, and medical applications. ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Inception Technologies to Release New Biometric Reader 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
... LONDON , April 27, 2010 Dominio Amigo S.A.S ... the .CO domain name launch. , , ... Julio Camacho , CEO, Dominio Amigo S.A.S , ... have consistently performed,at both ccTLD and gTLD launches, securing the very best Internet ...
... LONDON , April 27, 2010 ... backdrop. In,a video interview with online financial broadcaster http://www.cantos.com ,Chief Executive ... which,demonstrates the resilience of our business and the success of our enhanced,focus ... ...
... , April 27 The PMI Group, Inc. (NYSE: ... sell in concurrent underwritten public offerings an aggregate of 77,765,000 shares ... $6.15 per share and $261 million aggregate ... connection with the offerings, PMI has granted the underwriters 30-day options ...
Cached Biology News:Dominio Amigo Announce Domainmonster as .CO Technical Partner 2Dominio Amigo Announce Domainmonster as .CO Technical Partner 3Imperial Tobacco - 2010 Half Year Results Interviews 2The PMI Group, Inc. Announces Pricing of Common Stock and Convertible Senior Notes Offerings 2The PMI Group, Inc. Announces Pricing of Common Stock and Convertible Senior Notes Offerings 3The PMI Group, Inc. Announces Pricing of Common Stock and Convertible Senior Notes Offerings 4
... Precision-designed for Optimal Microdissection , CapSure ... the precise and rapid extraction of populations ... cytology samples with Laser Capture Microdissection., ... Downstream Molecular Analysis , All CapSure LCM ...
Opticon continuous fluorescence detector; includes optical base, analysis software, computer and monitor (this is an accessory for the DNA Engine thermal cyclers which must be ordered seperately)...
... ChipReader systems are highly sensitive laser confocal ... These are advanced scanners that meet your ... background level, and optimizing the signal on ... end of the range for increased sensitivity. ...
Bio-Plex Manager software, version 3.0, 5 license netshare, is a five-user software package that provides access to data from the Bio-Plex suspension array system from a server. This version does not...
Biology Products: